Famotidine (Famit)
Famotidine
Pharma-q Holdings (Pty) Ltd
Registration
- Applicant
- Pharma-q Holdings (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Famit 20 EACH TABLET CONTAINS FAMOTIDINE 20,0 mg | 20 | 32040832/11.4.3/0408 | Registered | Not determined | None |
| Famit 40 EACH TABLET CONTAINS FAMOTIDINE 40,0 mg | 40 | 32040932/11.4.3/0409 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Famotidine
- except when intended for the short term symptomatic relief of heartburn caused by excess acid, where the maximum dose is 10 milligrams, the maximum daily dose (per 24 hours) is 20 milligrams and the maximum treatment period is 2 weeks. (S2)
Consolidated Schedules 06 July 2026, lines 6306 to 6308
S2: Famotidine
- when intended for the short-term symptomatic relief of heartburn caused by excess acid, subject to -
- a maximum dose of 10 milligrams;
- a maximum daily dose (per 24 hours) of 20 milligrams;
- a maximum treatment period of 2 weeks. (S4)
Consolidated Schedules 06 July 2026, lines 1960 to 1967
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
3-[[2-(Diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
Drag to rotate. Structure from PubChem CID 5702160.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.